Immunogenicity of Pfizer mRNA COVID-19 vaccination followed by J&J adenovirus COVID-19 vaccination in two CLL patients.

Zoe L LyskiSunny KimDavid Xthona LeeDavid SampsonHans P RauéVikram RaghunathanDebbie RyanAmanda E BruntonMark K SlifkaWilliam B MesserStephen E Spurgeon

Published in: medRxiv : the preprint server for health sciences (2021)

The results of this study, however small, is especially promising to CLL individuals who did not seroconvert following initial mRNA vaccination series. Especially those that are treatment naive, not currently in active treatment, or who may consider vaccination before beginning active treatment.

Keyphrases

coronavirus disease
sars cov
newly diagnosed
ejection fraction
end stage renal disease
combination therapy
prognostic factors
binding protein